Stock ICCM ICECURE MEDICAL LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Delayed Nasdaq
Other stock markets
 12:05:24 2024-07-09 pm EDT 		5-day change 1st Jan Change
0.7524 USD +0.59% Intraday chart for IceCure Medical Ltd +1.50% -29.68%
Jul. 01 U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes CI
Jun. 04 FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
PR
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
PR
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes
CI
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
PR
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference, Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
AQ
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
PR
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan
PR
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025
CI
IceCure Medical : Company Presentation
PU
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024
AQ
Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000
MT
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase
PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally
PR
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024
CI
IceCure Medical : Company Presentation
PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization
AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer
MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ICCM Stock
  4. News IceCure Medical Ltd